China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Set to Reverse Split on Tuesday, February 3rd

Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) are set to reverse split before the market opens on Tuesday, February 3rd. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, February 2nd.

China SXT Pharmaceuticals Price Performance

Shares of SXTC stock traded down $0.02 during trading hours on Friday, reaching $0.03. 64,536,454 shares of the company were exchanged, compared to its average volume of 36,097,512. China SXT Pharmaceuticals has a fifty-two week low of $0.03 and a fifty-two week high of $7.84. The stock’s fifty day moving average is $1.05 and its two-hundred day moving average is $1.37.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its quarterly earnings results on Wednesday, December 31st. The company reported ($0.03) earnings per share for the quarter. The company had revenue of $0.31 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in China SXT Pharmaceuticals stock. Virtu Financial LLC grew its position in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) by 107.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,983 shares of the company’s stock after purchasing an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 at the end of the most recent reporting period. 5.02% of the stock is owned by institutional investors and hedge funds.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.